de Planque B A
Merwede Hospital, Dordrecht, The Netherlands.
Am Heart J. 1991 Jan;121(1 Pt 2):304-11. doi: 10.1016/0002-8703(91)90863-d.
The antihypertensive efficacy and safety of doxazosin (once daily) and prazosin (twice daily) were compared in patients with mild or moderate essential hypertension (diastolic blood pressure [DBP] 95 to 114 mm Hg) not adequately controlled by diuretics and beta-blockers. Doxazosin produced significantly greater mean reductions in standing (p = 0.01) and supine (p = 0.04) DBP than did prazosin; there were no significant between-group differences in either mean systolic blood pressure or heart rate. The overall mean daily doses for efficacy-evaluable patients were 4.7 mg of doxazosin and 6.7 mg of prazosin. Sixteen patients (84.2%) treated with doxazosin and 13 patients (56.5%) treated with prazosin were considered therapeutic successes (decrease in standing DBP greater than or equal to 10 mm Hg or to less than or equal to 90 mm Hg with greater than or equal to 5 mm Hg reduction from baseline). Of the 19 efficacy-evaluable patients treated with doxazosin, 15 (78.9%) showed improvement in the severity category of hypertension; an improvement in severity was reported in 14 patients (60.9%) treated with prazosin. Doxazosin produced a more favorable effect on serum lipid levels than did prazosin, although no statistically significant within- or between-group differences were observed. Most side effects experienced with either doxazosin or prazosin were mild or moderate and were tolerated or disappeared with continued treatment. The overall evaluation of toleration was excellent or good for 18 (90%) doxazosin- and 21 (91%) prazosin-treated patients. Clinical efficacy was rated as excellent or good for 16 patients (80%) treated with doxazosin and 15 patients (68%) treated with prazosin.
对轻度或中度原发性高血压（舒张压[DBP]95至114mmHg）且未被利尿剂和β受体阻滞剂充分控制的患者，比较了多沙唑嗪（每日一次）和哌唑嗪（每日两次）的降压疗效及安全性。多沙唑嗪使站立位（p = 0.01）和仰卧位（p = 0.04）DBP的平均降低幅度显著大于哌唑嗪；两组间平均收缩压或心率无显著差异。可评估疗效患者的总体日均剂量分别为多沙唑嗪4.7mg和哌唑嗪6.7mg。16例（84.2%）接受多沙唑嗪治疗的患者和13例（56.5%）接受哌唑嗪治疗的患者被视为治疗成功（站立位DBP降低大于或等于10mmHg或小于或等于90mmHg，且较基线降低大于或等于5mmHg）。在19例接受多沙唑嗪治疗的可评估疗效患者中，15例（78.9%）高血压严重程度分级有所改善；接受哌唑嗪治疗的14例患者（60.9%）报告严重程度有所改善。多沙唑嗪对血脂水平的影响比哌唑嗪更有利，尽管组内或组间未观察到统计学上的显著差异。多沙唑嗪或哌唑嗪引起的大多数副作用为轻度或中度，持续治疗时可耐受或消失。18例（90%）接受多沙唑嗪治疗和21例（91%）接受哌唑嗪治疗患者的总体耐受性评估为优或良。16例（80%）接受多沙唑嗪治疗和15例（68%）接受哌唑嗪治疗患者的临床疗效被评为优或良。
